Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus Update of the evidence-based guideline of the German Diabetes Association

被引：67

作者：

Matthaei, S. ^{[1
]}

Bierwirth, R.

Fritsche, A. ^{[2
]}

Gallwitz, B. ^{[2
]}

Haering, H. -U. ^{[2
]}

Joost, H. -G. ^{[3
]}

Kellerer, M. ^{[4
]}

Kloos, Ch. ^{[5
]}

Kunt, T.

Nauck, M. ^{[6
]}

Schernthaner, G. ^{[7
]}

Siegel, E. ^{[8
]}

Thienel, F. ^{[1
]}

机构：

[1] Diabet Zentrum Quakenbruck, Quakenbruck, Germany

[2] Univ Tubingen, Med Klin 4, Tubingen, Germany

[3] Deutsch Inst Ernahrungsforsch, Bergholz Rehbrucke, Germany

[4] Marienhosp Stuttgart, Zentrum Innere Med Diabetol & Endokrinol 1, Stuttgart, Germany

[5] Univ Jena, Klin Innere Med 3, Jena, Germany

[6] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany

[7] Krankenhaus Rudolfstiftung, Med Abt 1, Vienna, Austria

[8] St Vincentius Kliniken 1, Karlsruhe, Germany

来源：

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2009年 / 117卷 / 09期

关键词：

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; METFORMIN-TREATED PATIENTS; IMPROVES GLYCEMIC CONTROL; SULFONYLUREA PLUS METFORMIN; CARDIOVASCULAR RISK-FACTORS; ACUTE MYOCARDIAL-INFARCTION; DRUG-NAIVE PATIENTS; TO-TARGET TRIAL; PLASMINOGEN-ACTIVATOR INHIBITOR; INSULIN COMBINATION THERAPY;

D O I：

10.1055/s-0029-1239559

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：522 / 557

页数：36

共 286 条

[51] Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial [J].

Derosa, G ;

Gaddi, AV ;

Ciccarelli, L ;

Fogari, E ;

Ghelfi, M ;

Ferrari, I ;

Cicero, AFG .

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 (03) :284-294

[52] Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome [J].

Derosa, G ;

Gaddi, AV ;

Piccinni, MN ;

Ciccarelli, L ;

Salvadeo, S ;

Peros, E ;

Ghelfi, M ;

Ferrari, I ;

Cicero, AFG .

PHARMACOTHERAPY, 2005, 25 (05) :637-645

[53] Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride [J].

Derosa, G ;

Cicero, AFG ;

D'Angelo, A ;

Gaddi, A ;

Ragonesi, PD ;

Piccinni, MN ;

Salvadeo, S ;

Ciccarelli, L ;

Pricolo, F ;

Ghelfi, M ;

Ferrari, F ;

Montagna, L ;

Fogari, R .

HYPERTENSION RESEARCH, 2005, 28 (11) :917-924

[54] Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial [J].

Derosa, G ;

Gaddi, AV ;

Piccinni, MN ;

Salvadeo, S ;

Ciccarelli, L ;

Fogari, E ;

Ghelfi, M ;

Ferrari, I ;

Cicero, AFG .

DIABETES OBESITY & METABOLISM, 2006, 8 (02) :197-205

[55] Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [J].

Diamond, George A. ;

Bax, Leon ;

Kaul, Sanjay .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :578-581

[56] Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study [J].

Dills, DG ;

Schneider, J ;

Aronoff, SL ;

Azorr, MA ;

Brunner, D ;

Cefalu, WT ;

Cohen, AJ ;

Cyrus, J ;

Freedman, Z ;

Haag, BL ;

Hamilton, BP ;

Littlejohn, TW ;

Lucas, CP ;

Matlock, JS ;

McGill, JB ;

Miller, SS ;

Nikolai, T ;

Ogilvie, JT ;

Podlecki, DA ;

Ricaurte, M ;

Roudebush, CP ;

Singh, SP ;

Smulovitz, J ;

Soler, NG ;

Stone, J ;

Stonesifer, LD ;

Tucker, WS ;

Wallum, BJ ;

White, J ;

Whittier, FC ;

Zieve, FJ .

HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :426-429

[57] Intensive glycemic control in the ACCORD and ADVANCE trials [J].

Dluhy, Robert G. ;

McMahon, Graham T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2630-2633

[58] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[59] Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl(R)): A double-blind comparison with glibenclamide [J].

Draeger, KE ;

WernickePanten, K ;

Lomp, HJ ;

Schuler, E ;

Rosskamp, R .

HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :419-425

[60] Nateglinide [J].

Dunn, CJ ;

Faulds, D .

DRUGS, 2000, 60 (03) :607-615

← 1 2 3 4 5 6 7 8 9 10 →